Urispas (generic name: flavoxate hydrochloride) is an antispasmodic agent specifically formulated to provide symptomatic relief for bladder-related discomfort. It works by relaxing the smooth muscle of the urinary tract, thereby reducing spasms, urgency, frequency, and dysuria associated with various urological conditions. This medication is commonly prescribed for patients experiencing overactive bladder symptoms, cystitis, prostatitis, or following urological procedures. Its targeted mechanism offers a non-narcotic, non-analgesic approach to managing functional urinary disturbances, making it a valuable option in urological therapeutics under proper medical supervision.

Features

• Active ingredient: Flavoxate hydrochloride 100 mg
• Pharmaceutical form: Film-coated tablet
• Rapid onset of action, typically within 60 minutes
• Selective action on urinary tract smooth muscle
• Non-sedating formula with minimal central nervous system effects
• Convenient oral administration

Benefits

• Effectively reduces painful bladder spasms and cramping
• Decreases urinary urgency and frequency, improving daily comfort
• Alleviates dysuria (painful urination) associated with inflammatory conditions
• Enhances bladder capacity by reducing involuntary contractions
• Supports improved sleep quality by reducing nocturia episodes
• Provides targeted relief without general analgesic or anti-inflammatory effects

Common use

Urispas is primarily indicated for the symptomatic relief of various urological conditions characterized by smooth muscle spasm. These include cystitis (both bacterial and interstitial), urethritis, prostatitis, and urethrocystitis/trigonitis. It is also utilized for managing overactive bladder symptoms such as urgency, frequency, and incontinence. Post-operative and post-instrumentation applications are common following urological procedures where bladder irritation is anticipated. The medication addresses the symptoms rather than the underlying cause, making it appropriate as adjunctive therapy while definitive treatment is pursued.

Dosage and direction

The recommended adult dosage is one 100 mg tablet three to four times daily. Tablets should be swallowed whole with a full glass of water, with or without food, though administration with meals may minimize potential gastrointestinal discomfort. Dosage adjustments may be necessary for elderly patients or those with hepatic impairment. Treatment duration varies based on symptom resolution and underlying condition, typically ranging from several days to weeks. Patients should not exceed the prescribed dosage without medical consultation. Pediatric dosing has not been established, and the medication is generally not recommended for children under 12 years.

Precautions

Patients with glaucoma should use Urispas with caution due to potential anticholinergic effects that may increase intraocular pressure. Those with gastrointestinal obstructive disorders, such as paralytic ileus, should be carefully monitored. Hepatic impairment requires dosage consideration as flavoxate is metabolized in the liver. Elderly patients may experience increased sensitivity to anticholinergic effects, including confusion or dizziness. Driving or operating machinery should be avoided until individual response is determined. Pregnancy category B: use only if clearly needed after risk-benefit assessment. Nursing mothers should consult their physician as excretion in human milk is unknown.

Contraindications

Urispas is contraindicated in patients with known hypersensitivity to flavoxate hydrochloride or any component of the formulation. It should not be used in individuals with gastrointestinal obstruction, significant urinary retention, or uncontrolled narrow-angle glaucoma. Severe ulcerative colitis or toxic megacolon also represent absolute contraindications. Patients with myasthenia gravis should avoid this medication due to its antimuscarinic properties. Concomitant use with other anticholinergic agents is generally contraindicated due to additive effects.

Possible side effects

Common side effects (≥1%) include dry mouth, nausea, vomiting, blurred vision, dizziness, headache, and drowsiness. Less frequently reported effects (0.1-1%) include constipation, abdominal discomfort, tachycardia, nervousness, and insomnia. Rare adverse reactions (<0.1%) may include urticaria, mental confusion (particularly in elderly patients), increased intraocular pressure, and difficulty with micturition. Most side effects are dose-dependent and often diminish with continued therapy. Patients should report persistent or severe reactions to their healthcare provider.

Drug interaction

Concomitant use with other anticholinergic agents may potentiate both therapeutic and adverse effects. Monoamine oxidase inhibitors (MAOIs) may enhance anticholinergic activity. Urispas may affect gastrointestinal motility, potentially altering the absorption of other medications. Concurrent use with sedatives or alcohol may enhance central nervous system depression. The drug may interfere with diagnostic tests for urinary 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA). Always inform healthcare providers of all medications, including over-the-counter products and supplements.

Missed dose

If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Patients should not double the dose to make up for a missed administration. Consistent dosing maintains therapeutic blood levels, so establishing a routine is recommended. If multiple doses are missed or uncertainty exists, consult the prescribing physician for guidance.

Overdose

Symptoms of overdose may include severe anticholinergic effects: extreme dry mouth, dilated pupils, blurred vision, gastrointestinal paralysis, urinary retention, tachycardia, hyperthermia, and central nervous system disturbances ranging from excitement to convulsions followed by respiratory depression. Treatment is primarily supportive and symptomatic. Gastric lavage may be considered if ingestion was recent. Activated charcoal may be administered. Physostigmine may be used in severe cases but requires careful cardiac monitoring. Maintain adequate hydration and monitor vital signs closely.

Storage

Store at controlled room temperature (20-25°C or 68-77°F) in the original container. Protect from light, moisture, and excessive heat. Keep tightly closed and out of reach of children and pets. Do not transfer tablets to other containers as this may affect stability. Do not use if the packaging is damaged or tablets show signs of deterioration. Proper disposal of expired or unused medication should follow local regulations, typically through medication take-back programs.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Individual response to medication may vary. Urispas is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Patients should not initiate, discontinue, or change dosage without medical consultation. The complete prescribing information should be consulted before administration. This summary does not include all possible information about this medication.

Reviews

Clinical studies demonstrate Urispas provides significant symptomatic improvement in 70-80% of patients with bladder spasm-related conditions. Patients report measurable reduction in urinary frequency (typically decreasing from 10-12 to 5-7 daily voids) and urgency episodes within the first week of treatment. Quality of life assessments show improvement in sleep continuity and daily activities. Healthcare providers note the medication’s value in managing symptoms while awaiting culture results or definitive treatment. The favorable side effect profile compared to older antispasmodics is frequently cited. Long-term experience supports its utility in chronic conditions when used appropriately.